Search: Look for:   Last 1 Month   Last 6 Months   All time

New test to better predict breast cancer outcomes discovered

Washington , Fri, 28 Jan 2011 ANI

Washington, Jan 28 (ANI): Scientists have discovered a gene signature that can accurately predict which breast cancer patients are at risk of relapse, thereby sparing those who are not from the burdens associated with unnecessary treatment.

 

The discovery was made by researchers from McGill University's Rosalind and Morris Goodman Cancer Research Centre (GCRC), the Research Institute of the McGill University Health Centre (RI MUHC), the Dana-Farber Cancer Institute and Harvard Medical School.

 

For years, clinicians have been faced with the problem that breast cancer cannot be treated with a one-size-fits-all approach.

 

Some cancers respond to specific treatments while others do not. Close to 50 per cent of breast cancer patients belong to a group - defined as "estrogen receptor positive/lymph node negative (ER?)"- that is at low risk of relapse.

 

The majority of patients in this group may not require any treatment beyond the surgical removal of their tumour, while a small minority should receive additional treatment.

 

"The added information provided by our test would enable oncologists to identify those at very low risk of relapse, for whom the risk-benefit ratio might be in favour of withholding chemotherapy, and to identify patients in this low-risk group who would benefit from more aggressive treatments," explains Dr. Alain Nepveu, GCRC and RI MUHC researcher and co-author of the study.

 

"Since many treatments are associated with short- and long-term complications including premature menopause, cardiotoxicity and the development of secondary cancers, risks must be balanced against the potential benefit for each patient to avoid unnecessary suffering, needless expense and added burdens on the health-care system."

 

While more research is required before the test would be ready for market and incorporated into existing diagnostic procedures, Nepveu suggests it has the potential to be commercialized within five years.

 

These findings were published in a recent issue the Proceedings of the National Academy of Sciences. (ANI)

 


Read More: Cancer

LATEST IMAGES
Manohar Lal being presented with a memento
Manoj Tiwari BJP Relief meets the family members of late Ankit Sharma
Haryana CM Manohar Lal congratulate former Deputy PM Lal Krishna Advani on his 92nd birthday
King of Bhutan, the Bhutan Queen and Crown Prince meeting the PM Modi
PM Narendra Modi welcomes the King of Bhutan
Post comments:
Your Name (*) :
Your Email :
Your Phone :
Your Comment (*):
  Reload Image
 
 

Comments:


 

OTHER TOP STORIES


Excellent Hair Fall Treatment
Careers | Privacy Policy | Feedback | About Us | Contact Us | | Latest News
Copyright © 2015 NEWS TRACK India All rights reserved.